Terms: = Breast cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Clinical Outcome
3 results:
1. A Cyclin D1-Dependent Transcriptional Program Predicts clinical outcome in Mantle Cell Lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract] [Full Text] [Related]
2. Downregulation of mcl-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.
Li H; Liu L; Chang H; Zou Z; Xing D
Cell Death Dis; 2018 Jan; 9(2):137. PubMed ID: 29374168
[TBL] [Abstract] [Full Text] [Related]
3. Androgen receptor status predicts response to chemotherapy, not risk of breast cancer in Indian women.
Chintamani ; Kulshreshtha P; Chakraborty A; Singh L; Mishra AK; Bhatnagar D; Saxena S
World J Surg Oncol; 2010 Aug; 8():64. PubMed ID: 20831839
[TBL] [Abstract] [Full Text] [Related]
